Last reviewed · How we verify
Infuvite Adult (Nicotinamide)
At a glance
| Generic name | Nicotinamide |
|---|---|
| Also known as | Enduramide, Niacin (Vitamin B3), niacinamide, Decitabine, Tetrahydrouridine |
| Sponsor | Pfizer |
| Drug class | Standardized Chemical Allergen [EPC] |
| Target | NAD-dependent protein deacetylase sirtuin-2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Acne vulgaris
- Niacin deficiency
- Pellagra
Common side effects
- Rash
- Erythema
- Pruritis
- Headache
- Dizziness
- Agitation
- Anxiety
- Diplopia
Serious adverse events
- Anaphylaxis
- Anaphylactoid reactions
- Shortness of breath
- Wheezing
- Angioedema
- Allergic reactions to thiamine
- Hypervitaminosis A
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (EARLY_PHASE1)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (PHASE4)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infuvite Adult CI brief — competitive landscape report
- Infuvite Adult updates RSS · CI watch RSS
- Pfizer portfolio CI